CAR-T细胞治疗对CD19弱阳性B-ALL有效但受先前博纳吐单抗治疗影响
该研究分析了166例接受CAR-T细胞治疗的B-ALL患者,发现CD19弱阳性白血病对CAR-T细胞疗效与CD19正常或强阳性无显著差异,但先前使用博纳吐单抗与显著更高的未达MRD阴性缓解或抗原逃逸后复发率相关。
要点
- CD19弱阳性B-ALL对CAR-T细胞治疗有效,与CD19正常或强阳性无显著差异。
- 先前博纳吐单抗治疗与显著更高的CAR-T治疗失败或抗原逃逸后复发相关。
- CD19阳性白血病复发与CAR-T细胞功能丧失相关,CD19阴性复发与CAR-T细胞功能持续相关。
核心结论
- CAR-T细胞治疗对CD19弱阳性B-ALL有效,但先前博纳吐单抗治疗与显著更高的治疗失败或抗原逃逸后复发率相关。
研究设计与样本
- 单中心回顾性分析166例接受CAR-T细胞治疗的B-ALL患者。
主要发现
- CD19阳性白血病复发与CAR-T细胞功能丧失相关,CD19阴性白血病复发与CAR-T细胞功能持续相关。
- CD19弱阳性B-ALL与CD19正常或强阳性B-ALL相比,CAR-T细胞疗效无显著差异。
- 体外实验显示CAR-T细胞可识别并裂解CD19表达水平极低的细胞。
- 流式细胞术检测到CD19弱阳性或罕见CD19阴性事件不能预测CAR-T细胞治疗无反应或复发。
临床怎么用
- CD19弱阳性B-ALL患者可考虑CAR-T细胞治疗,不应仅因CD19表达弱而排除。
- 有博纳吐单抗治疗史的患者接受CAR-T细胞治疗时需警惕更高的失败和抗原逃逸复发风险。
局限性
- 单中心回顾性研究,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product targeting CD19 is approved for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of pretreatment variables, such as CD19 expression level, on leukemic blasts, the presence of CD19- subpopulations, and especially prior CD19-targeted therapy, on the response to CAR T-cell therapy has not been determined. We analyzed 166 patients treated with CAR T-cell therapy at our institution. Eleven patients did not achieve a minimal residual disease (MRD)- deep remission, whereas 67 patients had a recurrence after achieving a MRD- deep remission: 28 patients with CD19+ leukemia and 39 patients with CD19- leukemia. Return of CD19+ leukemia was associated with loss of CAR T-cell function, whereas CD19- leukemia was associated with continued CAR T-cell function. There were no significant differences in efficacy of CAR T cells in CD19-dim B-ALL, compared with CD19-normal or -bright B-ALL. Consistent with this, CAR T cells recognized and lysed cells with very low levels of CD19 expression in vitro. The presence of dim CD19 or rare CD19- events by flow cytometry did not predict nonresponse or recurrence after CAR T-cell therapy. However, prior therapy with the CD19-directed, bispecific T-cell engager blinatumomab was associated with a significantly higher rate of failure to achieve MRD- remission or subsequent loss of remission with antigen escape. Finally, immunophenotypic heterogeneity and lineage plasticity were independent of underlying clonotype and cytogenetic abnormalities.
引用
- Pillai V, Muralidharan K, Meng W, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019. PMID: 31738832. doi:10.1182/bloodadvances.2019000692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。